{"id":674,"date":"1998-03-01T12:01:00","date_gmt":"1998-03-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/verbesserte-vertraeglichkeit-von-dopamin-agonisten-in-der-behandlung-des-prolaktinoms-bei-initialer-gabe-von-prednisolon"},"modified":"1998-03-01T12:01:00","modified_gmt":"1998-03-01T11:01:00","slug":"verbesserte-vertraeglichkeit-von-dopamin-agonisten-in-der-behandlung-des-prolaktinoms-bei-initialer-gabe-von-prednisolon","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/verbesserte-vertraeglichkeit-von-dopamin-agonisten-in-der-behandlung-des-prolaktinoms-bei-initialer-gabe-von-prednisolon","title":{"rendered":"Verbesserte Vertr\u00e4glichkeit von Dopamin-Agonisten in der Behandlung des Prolaktinoms bei initialer Gabe von Prednisolon"},"content":{"rendered":"<p>Hypophysentumore, die Prolaktin sezernieren, f\u00fchren bei j\u00fcngeren Frauen zur hypogonadotropen Amenorrh\u00f6, beim Mann zu Libidomangel und Abfall des Serum-Testosterons. Kleine Prolaktinome (bis zu 1 cm Durchmesser), die \u00fcberwiegend bei Frauen diagnostiziert werden, nennt man Mikroprolaktinome, gr\u00f6\u00dfere Tumore Makroprolaktinome. Diese Tumore werden oft so gro\u00df, da\u00df sie zur Erblindung durch Druck auf das Chiasma opticum, zu [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hypophysentumore, die Prolaktin sezernieren, f\u00fchren bei j\u00fcngeren Frauen zur hypogonadotropen Amenorrh\u00f6, beim Mann zu Libidomangel und Abfall des Serum-Testosterons. Kleine Prolaktinome (bis zu 1 cm Durchmesser), die \u00fcberwiegend bei Frauen diagnostiziert werden, nennt man Mikroprolaktinome, gr\u00f6\u00dfere Tumore Makroprolaktinome. Diese Tumore werden oft so gro\u00df, da\u00df sie zur Erblindung durch Druck auf das Chiasma opticum, zu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[615,1661,1660,246,247,244,241,1662,1659],"class_list":["post-674","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-bromocriptin","tag-cabergolin","tag-dopamin-agonisten","tag-glukokortikoide","tag-glukokortikosteroide","tag-kortikosteroide","tag-prednisolon","tag-prolaktinom","tag-quinagolid"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=674"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/674\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}